In particular, activation of the PI3K/AKT signaling pathway and enhanced signaling from HER family receptors, including overexpression of HER3, are involved in mediating trastuzumab resistance in HER2-positive GC cells [14,15,16,17,18,19]. The gene discussed is ERBB2; the disease is gastric cancer.